Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Cytosorbents Cor (NQ: CTSO )

0.9300 +0.0100 (+1.09%)
Streaming Delayed Price Updated: 3:50 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 76,611
Open 0.9100
Bid (Size) 0.9300 (1)
Ask (Size) 0.9500 (1,655)
Prev. Close 0.9200
Today's Range 0.9063 - 0.9700
52wk Range 0.7000 - 2.150
Shares Outstanding 54,679,569
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India
From CytoSorbents; Converge Biotech
Via GlobeNewswire
CytoSorbents Reports Third Quarter 2024 Financial and Operational Results
From CytoSorbents
Via GlobeNewswire

Performance

YTD
-13.08%
-13.08%
1 Month
-10.58%
-10.58%
3 Month
-13.08%
-13.08%
6 Month
+7.89%
+7.89%
1 Year
-24.39%
-24.39%

More News

Read More
CytoSorbents Submits Health Canada Medical Device License Application for DrugSorb-ATR Following MDSAP Certification
From CytoSorbents
Via GlobeNewswire
Analyst Scoreboard: 5 Ratings For CytoSorbents
Via Benzinga
Expert Outlook: CytoSorbents Through The Eyes Of 5 Analysts
Via Benzinga
FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review
From CytoSorbents
Via GlobeNewswire
CytoSorbents to Report Third Quarter 2024 Operating and Financial Results
From CytoSorbents
Via GlobeNewswire
CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update
From CytoSorbents
Via GlobeNewswire
CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference
From CytoSorbents
Via GlobeNewswire
CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From CytoSorbents
Via GlobeNewswire
CTSO Stock Earnings: CytoSorbents Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
CytoSorbents Reports Second Quarter 2024 Financial and Operational Results
From CytoSorbents
Via GlobeNewswire
CytoSorbents Appoints Peter J. Mariani Chief Financial Officer
From CytoSorbents
Via GlobeNewswire
CytoSorbents to Report Second Quarter 2024 Operating and Financial Results
From CytoSorbents
Via GlobeNewswire
CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement
From CytoSorbents
Via GlobeNewswire
CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website
From CytoSorbents
Via GlobeNewswire
CytoSorbents to Present at the Inaugural American Association of Physicians of Indian Origin (AAPI) World Health Congress
From CytoSorbents
Via GlobeNewswire
Why CytoSorbents (CTSO) Stock Is Trading Higher
Via Benzinga
CytoSorbents Secures $20 Million Credit Facility
From CytoSorbents
Via GlobeNewswire
CytoSorbents Announces Regulatory Approval of CytoSorb® in Taiwan
From CytoSorbents
Via GlobeNewswire
CytoSorbents Announces the Launch and Immediate Availability of the PuriFi™ Blood Pump in the European Union
From CytoSorbents
Via GlobeNewswire
CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting
From CytoSorbents
Via GlobeNewswire
CytoSorbents STAR Registry Data on Patients on Ticagrelor Undergoing CABG Surgery with CytoSorb Presented at EuroPCR 2024. Named Top Five Finalist for Best Scientific Abstract
From CytoSorbents
Via GlobeNewswire
CTSO Stock Earnings: CytoSorbents Meets EPS, Beats Revenue for Q1 2024
Via InvestorPlace
CytoSorbents Reports First Quarter 2024 Results
From CytoSorbents
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.